Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ANDREA MIYAHIRA
The Prostate Cancer Foundation: A Discussion with Andrea Miyahira

VIEW ALL PCF VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH KENNETH PIENTA
The Process of Metastasis in Prostate Cancer

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

INTERVIEW WITH FRED SAAD
A Renewed Analysis of ERA 223

VIEW ALL ESMO VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Latest Videos
Featured Videos

ORLANDO, FL USA (UroToday.com) - The authors have previously demonstrated that a treatment dose of 2000 shock waves (SWs) produces a renal lesion and that this injury can be reduced:

(1) when SWs are delivered at a slower rate, or (2) when a priming dose of low-energy SWs is followed by a 3-4 minute pause. Although such protocols are effective at reducing injury, both of these modifications increase the required length of treatment time. Hence, the authors describe a new protocol offering renal protection and minimally increasing treatment time by using a 300 SW priming dose, with no pause.

auaSeven-week old juvenile pigs were first pretreated with 300 SWs at 12 kV (120 SWs/min), then treated after a 10 second pause with 2000 SWs at 24 kV, delivered to a lower pole calyx using a HM-3 lithotripter. Four hours later, the kidneys were fixed and processed for measuring the parenchymal lesion.

Six pigs were treated using the authors’ novel pause-less protocol, and were found to have lesions measuring 0.77±0.55% FRV (mean ± SE), compared to 3.31±1.06% FRV for a 2000 SWs dose at 24 kV. The results approached, but did not achieve, significance.

These preliminary data suggest that treatment with a pause-less protocol including 300 low-energy priming dose SWs shows promise in providing injury protection and short treatment length. These findings should undergo further study to determine whether the results are safely replicable in humans, before they can be adopted in the urology clinic.

Presented by Bret A. Connors, Ph.D at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Indiana University School of Medicine, Indianapolis, IN USA

Written by Eric Ballon-Landa, BA, University of California (Irvine), and medical writer for UroToday.com

 

Clinical Trials
Searchable data base of currently enrolling clinical trials
Journals
Publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 3 Issue 3

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe

Calendar
Upcoming educational events
December 13-16, 2018 / ESMO Immuno-Oncology Congress 2018
ESMO Immuno-Oncology Congress 2018
January 17-19, 2019 /
SNMMI 2019 Mid-Winter Meeting